Loading...
Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models
Erythropoietin (EPO) may be a beneficial tissue–protective cytokine. However, high doses of EPO are associate with adverse effects, including thrombosis, tumor growth, and hypertension. Carbamylated erythropoietin (CEPO) lacks both erythropoietic and vasoconstrictive actions. In this study, we compa...
Na minha lista:
| Udgivet i: | J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Nephrology
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084891/ https://ncbi.nlm.nih.gov/pubmed/26984884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015091059 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|